GlassScriptPhysician profile
Sajiv Sethi
NPI 1881014660
$65,349.43
in general payments reported to CMS, 2019-2025
40 companies · $57K in 2025
The $57K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2020: $17.75 · 2021: $203 · 2022: $775 · 2023: $3,276 · 2024: $3,387 · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Food and Beverage: $13K · Travel and Lodging: $4,142 · Education: $64.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,025.00 |
| Food and Beverage | $13,278.24 |
| Travel and Lodging | $4,142.28 |
| Education | $64.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $53,257.13 | 2024-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $2,452.58 | 2021-2025 | Rinvoq, Skyrizi, Mavyret |
| Pfizer INC. | $839.78 | 2023-2025 | |
| Covidien LP | $800.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $768.43 | 2020-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $650.25 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Genzyme Corporation | $590.97 | 2022-2025 | |
| Celgene Corporation | $589.06 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $456.42 | 2023-2025 | Ibsrela |
| Medtronic, INC. | $441.28 | 2022-2023 | Endoflip, Gi Genius, Pillcam |
| Lilly USA, LLC | $414.47 | 2024-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $391.62 | 2025 | Tremfya |
| Gilead Sciences, INC. | $354.94 | 2023-2025 | Livdelzi |
| Ferring Pharmaceuticals INC. | $340.61 | 2022-2025 | Rebyota, Clenpiq, Cimzia |
| Lucid Diagnostics INC. | $320.06 | 2022-2024 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $281.71 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $265.54 | 2023-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $238.04 | 2025 | Iqirvo |
| Boston Scientific Corporation | $227.10 | 2021-2024 | Watchman Flx |
| Celltrion USA INC. | $216.02 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Madrigal Pharmaceuticals | $173.35 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $145.93 | 2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $141.98 | 2022-2025 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $111.25 | 2023-2024 | Linzess |
| Redhill Biopharma INC. | $106.77 | 2023-2024 | Talicia, Movantik, Aemcolo |
| Novo Nordisk INC | $91.46 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $86.87 | 2023 | |
| Aimmune Therapeutics, INC. | $73.12 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.68 | 2023 | Cyltezo |
| Astrazeneca Pharmaceuticals LP | $49.03 | 2025 | |
| Orphalan INC | $47.28 | 2025 | Cuvrior |
| Intra-Sana Laboratories | $47.22 | 2023-2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Shire North American Group INC | $42.46 | 2019 | |
| Braintree Laboratories, INC. | $36.07 | 2022-2025 | Sutab, Suflave |
| Evoke Pharma, INC. | $30.32 | 2024-2025 | |
| Daiichi Sankyo INC. | $28.58 | 2023 | Injectafer |
| Fresenius Kabi USA, LLC | $26.00 | 2023 | Idacio |
| Intuitive Surgical, INC. | $23.33 | 2023 | |
| Pharmacosmos Therapeutics INC. | $15.91 | 2025 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajiv Sethi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.